Cardiotoxicity (CT) involving diminished cardiac contractility and heart failure is a major adverse event associated with otherwise efficacious protein kinase inhibitors (KIs). Here, we sought to develop clinically-weighted transcriptomic signatures to predict risk of CT and to better understand the biological processes associated with CT risk. We obtained transcriptome-wide response profiles in four human primary cardiomyocyte cell lines that were treated with 22 different KIs using mRNA sequencing with 3' digital gene expression. The FDA Adverse Event Reporting System was used to derive relative risk scores for four types of CT for different KIs. We used elastic net regression to associate these transcriptomic profiles with KI-associated risk scores for CT subtypes to obtain clinically-weighted transcriptomic signatures, which showed good predictive properties (cross-validation R 2 >0.87). Our clinically-weighted transcriptomic signatures for KI-associated CT may be of relevance in early drug development for the prediction of KI-associated CT.
INTRODUCTION
Protein kinase inhibitors (KIs) are a clinically important class of anticancer agents 1, 2 . There are currently more than 28 KIs 3 on the market, and more than 100 KIs in clinical development 4 . There are significant concerns regarding the safety profile of KIs. Cardiotoxicity (CT) is one clinically important adverse event associated with some KIs [5] [6] [7] . Typically, KI-associated CT manifests as loss of contractile function, which can subsequently lead to heart failure 8 . The human 'kinome' consists of more than 500 protein kinases 9 . Given that many KIs are not highly selective in the protein kinases they target 10 , the inhibition of any of these kinases in healthy cell types,
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Clinical risk profiles derived from FAERS show differences in risk profiles between cardiotoxicity subtypes
To obtain estimates of clinical risk of KI-associated CT, we analyzed data from the publicly accessible FDA Adverse Event Reporting System (FAERS) (Figure 2A) . We distinguished between four relevant subtypes of CT that can be identified from the FAERS database: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), ventricular dysfunction and heart failure (VDHF), and cardiotoxicity undefined (CTU). Subsequently, reporting odds ratios (RORs) and Z-scores were derived based on the relative frequencies of CT, for each KI present in the transcriptomics dataset ( Figure 2B ). For several KIs, there are observable differences in the risk for different subtypes of CT. The Z-scores were used as single metric to quantify CT risk, as it includes the confidence interval for the ROR. Here, the estimates for the ROR and associated Z-score indicate relative ranking of KIassociated toxicity, and not absolute risks of CT. Finally, using multivariate logistic regression analyses we estimated the effect of age and sex at 1.02 year -1 (2.6 CV%) and 1.47 (1.3 CV%), respectively. The low inter-KI variation of <2.6 CV% suggest that age and sex have negligible impact on individual KI-associated CT risk estimates.
Distinct and predictive signatures for 4 types of cardiotoxicity
Subsequently, we aimed to associate our KI-wide mean fold change gene expression profiles with the KI-specific clinical risk scores of four subtypes of CT (i.e. HCM, DCM, CTU, VDHF). Given the limited similarity between top ranking gene expression profiles across KIs ( Figure 1A-C) , the entirety of the gene expression profile across
KIs were considered as potential predictors for KI-associated CT risk. As such, KI-specific expression profiles of 9,281 genes were available as potential predictors for 22 KI-specific CT risk scores. To identify genes most strongly associated with CT risk we used an elastic net penalized regression approach, which is suited to identify predictors whilst limiting the risk of overfitting 20 . Separate models were fit for all four derived subtypes of CT. A two-stage regression analysis was performed (Figure 3 ). In the first stage, we constructed bootstrap datasets obtained after random resampling of KI risk and associated gene expression profiles, which were subsequently fit as elastic net models. This first step was performed to identify gene-based predictors that could consistently predict CT risk and contributed significantly to the prediction of this risk. The bootstrap analysis resulted in stable selection of potential predictors after 250 bootstrap samples ( Figure S1 ). Predictors to be included in the final elastic net regression model (Supplemental material 4) were selected based on their minimal root mean squared prediction error (RMSE, Figure S2 -3) after cross validation. Since we had only a limited number of KIs available, we explicitly chose to not keep apart any data for a full external validation. Instead, we evaluated model predictions using repeated random 3-fold cross validation for each of the four subtypes of CT, which resulted in high R 2 prediction metrics (>0.87) ( Figure 4A ). The selected gene expression-based predictors in the final elastic net model consisted of 42, 44, 44 and 85 genes for HCM, CTU, VDHF and DCM, respectively (Table S2, Figure   4B ). These sets of genes define our clinically-weighted transcriptomic signatures for cardiotoxicity; their 4 associated gene expression profiles are shown in Figure 4C . The importance of each of the selected genes for the prediction of CT risk was not equal (Figure 4B) . CT subtype DCM required 85 genes for optimal predictive performance, whereas for all other subtypes <44 genes were sufficient. Potentially, this is because not enough KIs with a diverse CT profile were available for deriving an informative gene signature. When assessing the similarity between each of the 4 clinically weighted gene expression signatures, the largest overlap was present between DCM and HCM (4 genes), VDHF and DCM (4 genes), and VDHF and HCM (2 genes) ( Figure 4D ). The genes FASTKD2 (FAST kinase domain containing protein 2) and MED19 (Mediator Of RNA Polymerase II Transcription, Subunit 19) were present in the signatures for HCM, VDHF and DCM. FASTKD2 plays a role in energy balance regulation in mitochondria under stress 21 . This could indeed be of relevance for cardiotoxicity, because mitochondrial dysfunction has been associated with cardiotoxicity 13, 22 , and this finding may warrant further detailed analysis.
Signatures for the 4 types of cardiotoxicity are enriched for different biological processes
In order to identify the potential functional consequences of our clinically-weighted transcriptomic signatures, we performed enrichment analyses based on the KEGG database, estimating over-representation of signature genes using Fisher's exact test ( Figure 5 ). Biological processes that appeared to be affected for all four types of CT included metabolic pathways, and common subcellular processes such as ribosome function, endocytosis, proteolysis, and splicing. However, similar to the differential clinical risks for the different types of cardiotoxicity, we observed distinct patterns in enriched subcellular processes for specific CT subtypes. Such differences include regulation of the actin cytoskeleton and oxidative phosphorylation for DCM, protein processing in the endoplasmic reticulum for HCM, VDHF), and apoptosis (DCM) amongst others ( Figure 5 ).
DISCUSSION
The occurrence of drug treatment associated cardiotoxicity leading to decreased cardiac contractility lags behind the therapeutic effects of the drugs and may only be observed in a subset of the patients using the drug. These two factors raise the question of whether it would be possible to obtain early cell based indicators of potential for drug toxicity. This study was designed to address this question. The approach we have used is to determine we can associate drug treatment induced gene expression patterns and the clinical risk for the adverse events of interest.
We estimated clinical risk from the FAERS database. Our use of FAERS is arguably a relevant and unbiased approach for the quantification of CT risk, because this data reflects unselected, real-life patients cohorts and may some of the potential bias associated with cohort selection associated with tightly controlled clinical trials. It is possible that risk metrics derived from controlled clinical trials can underestimate adverse event risks due to selective inclusion criteria of patients to demonstrate therapeutic efficacy, cohort size and duration of the trial.
5
Nevertheless there are limitations to the FAERS database as well that we have discussed and addressed in previous work 18 , and similarly address in this study. Figure   2B ). Nonetheless, the clinical classification of KI associated CT is an area that needs better resolution, and it is likely as EHR records become increasingly available that the data will become more detailed with respect to pathophysiology. Such improved clinical data can greatly enhance the value of analyses such as ours and aid in the drug development processes by contributing to early go/no-go decisions.
At the cellular level, commonly enriched subcellular processes associated with the clinically-weighted transcriptomic signatures included various metabolic processes, pathways related to oxidative phosphorylation, endoplasmic reticulum (ER) effects, and apoptosis. In addition, a number of subcellular processes related to transcription (ribosome, spliceosome), protein degradation and endocytosis were affected. Other recent studies into CT of anthracyclines and KIs agree with our findings that changes in metabolic processes 23, 24 , ER effects 14 , oxidative phosphorylation 13, 25 AMPK signaling 26 , cell adhesion 27 , cell survival pathways 12 , and the FoxO-related transcription 28 are likely to be involved. It is possible that gene expression profiles associated with specific 6 subcellular processes could be co-expressed and hence highly correlated. However, due to the nature of the elastic net regression algorithm used, highly correlated genes are unlikely to be selected simultaneously, limiting overrepresentation of the identification of associated subcellular pathways.
Besides variation in drug exposure, pharmacodynamic inter-individual variation in severity of CT is likely. The current group of four cell lines are not of sufficient size to realistically capture such human variability. Therefore, in our analysis, we used mean fold change gene expression profiles across multiple cell lines. The resulting averaged gene expression profiles thus reflect relatively consistent changes in gene expression across cell lines,
i.e. changes in gene expression that are less likely to be highly variable across individuals, yet may result in consistent predictors across the population. Given that the FAERS CT risk scores also reflect a population-level CT risk, the use of these mean values in fold-change gene expression values is a reasonable starting point for our
analyses.
The experimental underpinning of the transcriptomic profiles generated in this study make them likely to be of value in selecting drug candidates for human use. Our analysis is based on primary human derived cardiomyocytes.
Although these cell lines do have phenotypic limitations due to dedifferentiation 29 , the signatures obtained from the cells could be relevant for prediction of clinical drug effects. These cell lines may be reflective of specific human cardiac pharmacology 30, 31 , even though further characterization and standardization is still needed. Our analyses used drug exposures at estimated therapeutic concentrations of the individual KIs, rather than using the same concentrations for all KIs. We used the reported maximum concentrations as reported in literature (Table   S3 ). Here, we did not correct for protein binding, but, we consider that given the typical protein binding of >95% of these KIs, the concentration used may reflect patients with over-exposure to the KI. As such, the concentrations used are relevant to assess transcriptomic changes that are likely related to early changes in subcellular processes associated with the adverse event of interest.
We anticipate that clinically weighted transcriptomic signatures such as developed in this study may be of relevance to guide safety assessment in early drug development. Unlike the relatively well-established assessment of electrophysiological safety issues such as QT prolongation, the assessment of non-QT type of cardiotoxicity associated with KIs 12 and other novel drugs 32 , lack reliable biomarkers. Transcriptomic signatures could help fill this gap. Transcriptomic analyses may also guide the discovery of subcellular pathway based biomarkers that can be measured in both preclinical model systems as well as in patients in surrogate cells. Data on biomarker levels could then be included in PK-PD models to personalize dose regimens that limit risk of CT [33] [34] [35] , before the 7 appearance of imaging based indicators such as the left ventricular ejection fraction. The current study represents a starting point and many more studies both experimental and computational will be needed to utilize transcriptomic studies in drug development and clinical practice.
METHODS
Experiments to identify differentially expressed genes in human cardiomyocytes treated with KIs.
Adult human cardiomyoctes were purchased from PromoCell and grown in culture per manufacturer's instructions.
Four different cell lines representing different human subjects were studied. Cells were treated with a single dose at the estimated therapeutic concentration used in humans for 48 hrs (Table S3) . After drug treatment, the cells were lysed, RNA was collected using TRIzol, and gene expression profiles were measured using the 3' digital gene expression method 36, 37 . Details of the experimental protocols have been described in another study 38 and stepby-step standard operating procedures for the various experiments are available on www.dtoxs.org.
Sequence alignment and processing of gene expression data
The raw sequences were demultiplexed. Combined standard RNA-seq sequencing files were aligned to the reference human genome provided by the Broad Institute 36 , using the Burrows-Wheeler Alignment (BWA) 39 software. Details of these computational procedures are described elsewhere 38 , and step-by-step protocols are available on ww.dtoxs.org. The resulting alignment files were parsed to identify the fragments with acceptable alignment quality, to remove duplicate fragments, and to assign accepted fragments to corresponding genes. The resulting read-count (i.e., transcript count) table was then subjected to correlation analysis at each treatment condition, to identify and remove outlier samples, determined by predefined thresholds. The gene read-count tables were then subjected to differential gene expression analysis using the R package EdgeR 40 . The resulting normalized and log-transformed fold-change gene expression values for each sample were deposited for public access to the DtoxS repository (www.dtoxs.org).
Processing and exploratory analysis or gene expression data
The mean log transformed gene expression fold-change value was calculated across all cell lines for each individual KI. The resulting matrix of gene fold changes values by KIs was used for the regression analysis. To obtain insight in the general patterns present in this KI-perturbed transcriptomics dataset, we generated rankings of the top 500 genes for each drug, by their absolute fold change value. For each of these KI-associated rankings we determined the frequency of these changes being also present in the ranking of other drugs, e.g. the similarity in top ranking gene expression. This was visualized using the Jaccard index, and by plotting the most highly drugconnected genes against the associated drugs. Finally we performed on the mean fold-change values for each drug
Calculation of clinical risk scores
The FDA Adverse Event Reporting Systems (FAERS) raw data files were downloaded from the FDA website (all report files up to 2015 Q3). Adverse events in the raw data files were mapped to the MEDDRA dictionary 41 .
Subsequently we defined four types of CT, that were related to either hypertrophic cardiomyopathy, dilated cardiomyopathy, ventricular dysfunction and heart failure, and undefined cardiotoxicity. Electrophysiological forms of CT were excluded. The selection of the selected CT subtypes is provided in Table S1 . Since drug names in FAERS are of low quality, i.e. they contain many spelling mistakes, mixed brand names, or combinations of drugs associated with a single adverse event, we performed extensive curation on the drug names converting the drug name records to generic drug names. This was done using dictionaries from the FDA and DrugBank. We also applied a conservative fuzzy match algorithm to detect drug names with spelling errors. Through iterative manual checking and automated string matching using R we derived a curated database of drug names associated with adverse events. Subsequently, the frequency of CT events in the 4 predefined subgroups, other non-CT adverse events were computed for individual KIs included in our experiments, and for all other drugs. Based on this we 
Elastic net regression analysis
The FAERS-derived risk (Z-scores) for each of the four types of CT was regressed against the KI associated vectors of mean fold change values across the four cell lines. We chose to use Z-scores as metric reflecting CTrisk, as this metric takes into consideration the uncertainty of the reporting odds ratio. Prior to regression we filtered the gene lists by their presence in either the Gene Ontology Biological Processes, KEGG, Reactome, or
WikiPathways databases, in order to exclude genes for which no biological function has been established.
Subsequently we generated 250 bootstrap datasets with replacements. We did separate bootstrapping for each KI.
Each of these bootstrap datasets was fit using an elastic net regression model (R package glmnet). The selected genes that were selected as predictors (i.e. non-zero regression coefficient) and the scaled values of the geneassociated coefficients were saved for each bootstrap dataset. Across all bootstrap datasets the relative frequency of selection of gene-based predictors, and the mean scaled coefficient value of these coefficients was computed.
We then calculated the product of the mean frequency and scaled coefficient value, rank predictors by their importance with respect to robustness (selection frequency) and their importance. Different upper percentiles of these rankings were regressed against each CT subtype and evaluated using 3-fold cross validation. The selection percentile resulting in optimal prediction errors (RMSE) was then used to select a subset of gene based predictors,
and to select the model that generated the final gene expression signatures for each CT subtype. 
TABLES
... These  were: ZKSCAN7, ANAPC4, COPS4, SLC25A3, DAB2, PQLC2, ING5, MRPL18, NUP37, CLPX, MRPL51,  RBFA, ZDHHC20, ERBB2IP, MBOAT2, MALSU1, PLK2, GMDS, NADSYN1, WLS, ATG12, ENY2,  ZNF180, NR2C2, MED19, FAM175B, DLD, ZNF702P, SUCLG1, TIA1, ZNF28, PML, CBLB, ZMYM4,  ZSWIM7, KMT2E, NDUFA4, PDSS2  AZI2  INTS4  IDS  FASTKD2  PABPC1  RAF1  EIF4H  AGGF1  ATP5C1  ABI2  KMT2D  ATM  SRI  NAA20  NDUFA8  FKBP5  PXN  UBE2E1  TBC1D2B  RNF213  STX6  DCP2  POLK  MED27  RNPEP  ZSCAN32  NIT2  FH  DUSP14  NDUFAF1  ZNF675  NDUFA9  RIC8A  RAB24  GFM2  CSE1L  ADSL  TBC1D19  NBR1  RBM26  CEP152  GEMIN2  HERPUD2  TRIP4  ZKSCAN7  ANAPC4  COPS4  SLC25A3  DAB2  PQLC2  ING5  MRPL18  NUP37  CLPX  MRPL51  RBFA  ZDHHC20  ERBB2IP  MBOAT2  MALSU1  PLK2  GMDS  NADSYN1  WLS  ATG12  ENY2  ZNF180  NR2C2  MED19  FAM175B  DLD  ZNF702P  SUCLG1  TIA1  ZNF28  PML  CBLB  ZMYM4  ZSWIM7  KMT2E  NDUFA4  DST  ATG7  PCDHB7   IDS  FASTKD2  MED19  HAT1  NUP37  TPT1  POLD4  WLS  TRAPPC3  ASXL1  CHTOP  DHX33  PNPT1  LSM7  IMMT  NDUFA9  CHM  USP45  CHD8  KNSTRN  LONP2  XRN1  POLK  CDC73  ADSL  ZBTB24  TRIM52  EP400  USP8  CDIPT  DCLRE1B  KIAA0141  DROSHA  ANP32A  CLASP1  GGH  ISY1  RPA2  ATOX1  CLPX  MRPL18  RRAGA   RANGRF  ETFA  LUC7L  SPAST  ATXN10  ASXL1  WWP2  PDP2  DHX16  GTF2F2  CYP4V2  FBXL5  TMEM11  SPIRE2  ZC3H12D  EYA3  RNF10  SNRNP200  SNAP29  LYZ  ZNF483  SLC25A39  BRCA1  GHR  ZNF124  SURF6  CLDN16  CEACAM5  NANOG  SLC6A4  CDK16  PHF19  ARSA  PTCD1  RBFA  MAP3K6  PCDH11Y  ZNF432  ZNF543  CPT2  SETD1B  PDE10A  ZNF286A  IL16   NUP107  TUBGCP5  MED19  RNPEP  VPS53  AAMP  PRKD3  SNX14  ATXN2  FASTKD2  ARAF  B3GNT2  HECTD2  KIAA0196  RPA2  SPICE1  CPSF2  FBXO6  PACSIN2  USP3  CSTF1  TRUB1  ZSCAN25  ZRANB3  MLKL  SCO1  GMDS  GDE1  ZNF518B  DGKE  PLXDC1  EP400  MBOAT2  UTP20  RINL  NPLOC4  ZNF418  TAF1C  USP22  RBL1  TRIP4  HERPUD2  RIC8A  CHFR   Table S3 . Typical concentrations used for experiments (exposure for 48h). Concentrations were selected based on the mean maximum drug concentrations reported in clinical studies. For dose escalation studies the highest concentration was used.
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